Comparative Pharmacology
Head-to-head clinical analysis: HETLIOZ LQ versus TASIMELTEON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HETLIOZ LQ versus TASIMELTEON.
HETLIOZ LQ vs TASIMELTEON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melatonin receptor agonist; selectively binds to and activates MT1 and MT2 receptors in the suprachiasmatic nucleus, regulating circadian rhythms and promoting sleep.
Tasimelteon is a selective melatonin MT1 and MT2 receptor agonist that mimics the natural sleep-promoting effects of melatonin by modulating circadian rhythms. It binds to MT1 receptors to promote sleep onset and to MT2 receptors to phase-shift the circadian clock.
20 mg orally once daily at bedtime, taken within 30 minutes of bedtime with or without food. For delayed sleep-wake phase disorder: 0.5 mg/kg (up to 20 mg) once daily at bedtime.
20 mg orally once daily at bedtime, taken within 30 minutes of retiring and at the same time each night. Not to be taken with or immediately after a high-fat meal.
None Documented
None Documented
Clinical Note
moderateTasimelteon + Ketoconazole
"The serum concentration of Ketoconazole can be increased when it is combined with Tasimelteon."
Clinical Note
moderateTasimelteon + Venlafaxine
"The risk or severity of adverse effects can be increased when Tasimelteon is combined with Venlafaxine."
Clinical Note
moderateTasimelteon + Atazanavir
"The serum concentration of Atazanavir can be increased when it is combined with Tasimelteon."
Clinical Note
moderateTasimelteon + Clarithromycin
Terminal elimination half-life is approximately 1.5-2.0 hours; clinical context: dosing at bedtime aligns with short half-life to avoid residual daytime sedation.
1.3 hours (range 0.5–2.0 h); short half-life consistent with use for sleep initiation without residual sedation.
Primarily hepatic metabolism (CYP1A2, CYP3A4) with renal excretion of metabolites; unchanged tasimelteon in urine <1%; fecal excretion accounts for approximately 80% of total clearance.
Primarily hepatic metabolism via CYP1A2 and CYP3A4; <0.1% excreted unchanged in urine; fecal excretion accounts for ~80% of total clearance as metabolites.
Category C
Category C
Melatonin Receptor Agonist
Melatonin Receptor Agonist
"The serum concentration of Clarithromycin can be increased when it is combined with Tasimelteon."